Moroxite T is a medtech company incorporated in Sweden with a total issued and paid-up share capital of 25,000 Swedish krona, divided into 1,000 fully paid-in registered shares with a nominal value of 25 Swedish krona each. As a long-term project, Moroxite T is developing a new device or a combined pharma medtech product in the tumour area.
Rex International Holding’s wholly-owned subsidiary Moroxite Holding Pte. Ltd. has entered into a conditional share purchase agreement (SPA) with Moroxite AB on Dec 30.
Under the SPA, Moroxite Holding will purchase entire issued share capital of Moroxite T AB comprising 1,000 shares at a nominal consideration of 1 Swedish krona (13 cents) from Moroxite AB with a commitment to invest up to an additional 43.2 million Swedish krona ($5.6 million), subject to the fulfilment of certain conditions. The sum will be satisfied in cash.
